DE2356790A1 - Prevention and treatment of herpes infections - by oral or parenteral admin of methenamine - Google Patents

Abstract

Compsns for prophylaxis or treatment of herpes virus infections contain methenamine (I) and/or its derivs as active ingredient. (I) is active against herpes zoster and herpes simplex types I and II. The compsn may contain other active medicaments, vits., analgesics, chemotherapeutics and/or antibiotics. Derivs of (I) include salts with org. or (in)org. acids cpds with salts such as MgCl2, CaCl2 or Na acetate or cpd with nonacidic org. cpds such as CH3Cl. The dose is generally 1g (I) 2-3 times/day and should not excess 6g/day.

Description

Therapeutic drug against herpes virus diseases

The present invention is concerned with a heretofore unknown Effect of the well-known chemical compound methenamine with the structural formula given below

HjC-

CH ₂

H ₃

Molecular formula: CH, J
Molecular weight: 140.9 and its compounds:

1. Compounds of methenamine with inorganic acids * e.g. hydrochloric acid or phosphoric acid,

2. Salts of methenamine with organic compounds of acidic character, e.g. hydrochloric acid;

3. Compounds of methenamine with metal salts, e.g. magnesium chloride or calcium chloride,

4. Compounds of methenamine with salts (including complex acids), e.g. Sodium acetate,

5. Methenamine compounds with organic compounds are not acidic Character, e.g. methyl chloride,

B. functional derivatives of methenamine, e.g. methenamine hydroxyethylate.

The aforementioned compounds are effective according to the present invention against viral diseases, for the treatment of which, in particular peroral treatment, substances that have a reliable effect are not yet known.

The effectiveness of these substances according to the invention is aimed at both against herpes simplex viruses of the two according to the clinical presentation distinguishable types I and II as well as against the herpes zoster virus.

Depending on the clinical appearance, a distinction is made among the skin eruptions caused by the herpes simplex types

509820/1085

-2-

a) the primary infection - a one-time eruption

b) the occasionally recurrent course with intervals of 1-2 years j

c) Herpes recurring sive recurrens with frequent and often very regular occurring recurrences.

The following are assumed to cause these diseases:

1. Herpes simplex virus type I

2. Herpes simplex virus type II

3. Fish infection with type I and type II

Virus type I mainly causes eruptions on the face and on the oral mucous membranes and on the upper body, type II on the genitals, on the gluteal region and rarely also in the extremities. Types I and II can be distinguished serologically. The proportion of genital strains in recurrent herpes infections fluctuates between 37 and 58%.

According to recent study results, the herpes II virus can be very serious to intervene in the cell metabolism of the mucosal epithelium, especially of the female cervix. Under its influence, normal cells can grow into convert malignant cells. For example, there are significantly higher levels of antibodies against the herpes II virus in patients with dysplasia and cervical cancer than in women with normal cervical epithelium, as well as in the tumor types lip, mouth, prostate, kidney, nasopharynx, vulvar carcinoma, so that The conviction has prevailed that the tumors mentioned with the pathogenetic involvement of the herpes simplex virus type I or type II or both can be caused at the same time.

Accordingly, there is one that is as easy to use as possible and, if possible, also per os safe herpes virus therapy effective per os, i.e. a therapy which is effective against the herpes simplex virus, type I and type II and against the herpes zoster virus is effective, of utmost importance. '' So far, the following treatment methods are known:

A. Parenteral use of type-specific herpes vaccines. This treatment has the disadvantage that the vaccine

509820/1095

still contains traces of protein and thus the possibility of allergies consists. The vaccination has to be carried out repeatedly with re-vaccinations every 3 - 6 months and results in a freedom from appearance of 77 - 78%. So it is not a guarantee of success given.

B. Chemotherapy drugs such as Thiosemi carbazone have had little success brought.

C. With the help of interferon, a protein formed as a defense body in the human organism, an attempt was made to prevent the virus from replicating within the cells. It was thus possible to shorten the course of the disease (length of stay of the virus) in herpes zoster sufferers from 31 days to M days and to reduce post-zoster neuritis from 18.7% of cases to 0.53% The organism was induced by treatment with influenza A virus, which is injected parenterally, which treatment must start as early as possible and be carried out every 12 hours for 4 days.

D. The zoster ophthalmicus is 2-7 days long with 80 mg furose daily been treated. A subjective improvement was thus achieved CG. Feiten, "dermatologist" 2! 3 C1972) 3: 140],

In contrast, methenamine is used according to the invention or its above compounds, the herpes disease quickly to heal.

The dosage is both oral and parenteral administration On average, 1, o g methenamine or a corresponding amount based on the molecular weight of its compounds listed above 2-3 times a day.

It does not matter whether methenamine alone or in a mixture with it these compounds or one of the compounds in admixture with other methenal compounds is given; The only thing that matters when it comes to the dosage level is the total amount of methenamine contained. The gravimetric ^

509820/1095

-4-

The size and frequency of the presentations should neither increase nor decrease are subject to a limit below. Smaller doses can be used just as well, and more frequently if necessary, or the entire daily amount all at once, expediently in a dosage form with delayed release of active ingredient, be applied. However, the total daily dose should be 6 g on methenamine, do not exceed.

Claims (8)

Claims (Tl medicinal preparations for the prevention or treatment of herpes virus diseases, Containing methenamine as an active ingredient. 2. Medicinal preparations for the prevention or treatment of herpes virus diseases, methenamine as an active ingredient in per os usable form as a powder, crystalline substance or under pressure Pressings deformed without any further addition of auxiliary materials. 3. Medicinal preparations for the prevention or treatment of herpes virus diseases, Containing methenamine as active ingredient, with additions of auxiliaries for tabletting, sugar-coating, production of film coatings or with the addition of substances for the production of protective coatings, which cover the individual active ingredient particles and / or with wrappings in In the form of capsules or wafers. 4. Medicinal preparations for the prevention or treatment of herpes virus diseases with the active ingredient methenamine in per os usable form with the addition of liquids and other auxiliaries for production of drops, juices, pastes and emulsions v 5. Medicinal preparations for preventing or treating herpes virus diseases with the active ingredient methenamine, but also containing other medicinally active substances in addition to this, e.g. vitamins, analgesic, chemotherapeutically and / or antibiotically active substances. 6. Medicinal preparations for the prevention or treatment of herpes virus diseases with the active ingredient methenamine in parenterally applicable 509820/1095 -5- Form, whereby the active ingredient methenamine is either already in an injectable solution or suspension, or in which undissolved methenamine and solvent are to be dissolved or Suspending the methenamine are located in different vessels. 7. Medicinal preparations for the prevention or treatment of herpes virus diseases, where the active ingredient methenamine together with other medicinally active substances such as vitamins, analgesic, chemotherapeutically and / or antibiotically active substances are already in an injectable solution or in suspension or the mixture of methenamine with other medicinally active substances and the solvent for dissolving or suspending them are in separate vessels. 8. Claim according to paragraphs 1-7, however, methenamine in whole or in part is replaced by one or more of its known compounds. 50 9 820/1095